What Happens After You Stop a GLP-1

Withdrawal arms in the major trials show most of the weight returning. That result deserves more attention than the headline loss.

The withdrawal extensions of the major incretin trials are the least-discussed and most decision-relevant part of the literature. When treatment stops, appetite suppression stops, and the majority of the lost weight returns over the following year — along with much of the improvement in blood pressure and glycaemic markers.

This is not a failure of the drug class. It is what happens with any treatment for a chronic condition when the treatment is removed, and framing it as relapse imports a moral reading that does not apply to antihypertensives.

Two practical consequences follow. Discontinuation should be planned rather than accidental, with a structured food and training pattern already in place. And composition matters more on the way down than the way up: if a large share of the loss was lean mass, regaining fat-dominant weight leaves someone metabolically worse off than before.

Resistance training twice a week and protein at the upper end of the recommended range are the two interventions with evidence for protecting lean mass through both phases. None of this is medical advice, and dose changes belong with the prescribing clinician.

The drugs work while they are being taken. That is the same sentence we accept for blood-pressure medication.

Editorial note: this article summarises published research for general information. It is not medical advice. Discuss any intervention with a qualified clinician.